These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31625890)

  • 1. [Exploiting DNA repair vulnerabilities with PARP inhibitors to stimulate anti-tumor immunity].
    Chabanon RM; Postel-Vinay S
    Med Sci (Paris); 2019 Oct; 35(10):728-731. PubMed ID: 31625890
    [No Abstract]   [Full Text] [Related]  

  • 2. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
    Francica P; Rottenberg S
    Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting backup DNA repair in cancer.
    Cancer Discov; 2015 Jun; 5(6):OF7. PubMed ID: 25851856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse the Resistance to PARP Inhibitors.
    Kim Y; Kim A; Sharip A; Sharip A; Jiang J; Yang Q; Xie Y
    Int J Biol Sci; 2017; 13(2):198-208. PubMed ID: 28255272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.
    Lheureux S; Mirza M; Coleman R
    J Clin Oncol; 2019 Sep; 37(27):2449-2459. PubMed ID: 31403862
    [No Abstract]   [Full Text] [Related]  

  • 9. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
    Lu Y; Liu Y; Pang Y; Pacak K; Yang C
    Pharmacol Ther; 2018 Aug; 188():168-175. PubMed ID: 29621593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for Homologous Recombination Deficiency in Cancer.
    Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
    J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
    Cipak L; Jantova S
    Neoplasma; 2010; 57(5):401-5. PubMed ID: 20568893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.